The International Congress for Lung Cancer and Head & Neck Cancer 2011 covers topics such as:
- Personalized maintenance therapy in lung cancer
- Lung cancer patients selection for personalized chemotherapy
- Adjuvant and neoadjuvant therapy in early stage lung cancer
- Patients education on the personalized and optimized multimodality therapy in the treatment of lung cancer
- Clinical data supporting the optimal use of EGFR TKI`s in the treatment of lung cancer based on biomarkers leading to change in practice
- Patient selection for integration of bevacizumab in the management of lung cancer
- HDAC inhibitors/ talactoferrin/STA 9090 and other HSP 90, c-met inhibitors, EGFL-7, ARQ197, farletuzumab/Hedge-Hog inhibitors that potentially improve upon standard chemotherapy and linifanib
- Managing primary and secondary resistance to anti-EGFR therapy in patients with lung cancer
- Symptom control and management of toxicities associated with chemotherapy and targeted agents
- Novel treatment strategies for small cell lung cancer
- Supportive cancer care in the era of targeted therapy
The International Congress for Lung Cancer and Head & Neck Cancer brings together radiation oncologists, primarily to medical oncologists, registered nurses, pharmacists, nurse practitioners interested in new developments for treatment of lung cancer and head & neck cancer and physician assistants.
